Primärquellen-Eintrag
EntscheidungsrelevantTopline-Ergebnisse
Invivyd VYD2311 DECLARATION Phase 3 Topline-Daten erwartet Q3 2026
DECLARATION pivotal trial enrollment is now complete with top-line data planned later in Q3 2026 to support potential BLA submission. LIBERTY Phase 3 trial is also fully dosed with top-line data anticipated in late Q3 2026.
Kernfakten
- Eingereicht
- 13. Aug. 2026, 20:11
- Ereignis
- Topline-Ergebnisse
- Richtung
- Neutral
- Unternehmen
IVVDInvivyd- Asset
- pemivibart
- Quelle
- SEC 8-K
- Belegstatus
- Belegt
Auszug aus der Quelle
EX-99.1 2 ivvd-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights • Achieved Q2 2026 PEMGARDA® (pemivibart) net product revenue of $14.3 million, representing 21% growth versus Q2 2025 net product revenue of $11.8 million • Completed rapid enrollment in VYD2311 DECLARATION clinical trial expansion cohort and LIBERTY clinical trial, driven by strong subject demand • DECLARATION pivotal clinical trial enrollment is complete; the ongoing study is approaching its planned analysis, and in lieu of a Q2 2026 quarterly earnings call, Invivyd plans to hold an investor call post study completion • LIBERTY study fully dosed with top-line data anticipated in late Q3 2026 • Strong balance sheet with Q2 2026 ending cash and